【必贝特】PCSK9/AGT双靶点siRNA获批1/2期IND，持续推荐【东吴医药朱国广团队】 事件：2月3日，必贝特的PCSK9/AGT双靶点siRNA获批我国1/2期IND，用于轻中度高血压合并低密度脂蛋白胆固 醇升高。 FIC靶点选择，我国top1、全球top2申报IND的双靶siRNA，公司专有的GDOC技术平台，#独特并联的结构设计， 有望实现稳定性更强的递送效果。 公司管线关注： 建议关注必贝特双靶点项目、CNS靶向递送、肾病递送等突破性进展。 – BEBT-507 TMPRSS6 真性红细胞增多症PV1期 – BEBT-701 AGT+PCSK9 高血压+高血脂 – BEBT-706 Lp(a)+PCSK9 ACSVD – BEBT-720 CIDEB+ HSD17B13 MASH – BEBT-758 SNCA 帕金森 – BEBT-756 APP+Tau阿尔茨海默病 – 以及高尿酸血症+痛风 、肾性贫血/CKD、糖尿病等管线 FIC靶点选择，我国top1、全球top2申报IND的双靶siRNA，公司专有的GDOC技术平台，#独特并联的结构设计， 有望实现稳定性更强的递送效果。 高血压患者全球 ...

Core Insights - The company is strategically expanding into the small RNA platform to address age-related chronic diseases, aiming to develop a pipeline with long-term value and transition into a Pharma company [1][2]. Group 1: Company Overview - The company has established a partnership with AditumBio to form KalexoBio, focusing on a dual-target siRNA drug, 2MW7141, for cardiovascular diseases, with a total deal value of $1 billion [2]. - The company has a strong asset management background, with the fund managing assets of 16.182 billion yuan and achieving a one-year return of 54.74% for its best-performing fund [1]. Group 2: Product Development - The dual-target siRNA drug 2MW7141 is designed to address unmet clinical needs in cardiovascular treatment, with preliminary data showing strong efficacy in animal models [3][5]. - The siRNA technology platform emphasizes differentiated innovation, utilizing AI for automated design and screening, and optimizing delivery methods for both liver-targeted and extrahepatic applications [4]. Group 3: Research and Clinical Trials - The α-synuclein-targeting PET tracer [18F]-FD4 has received funding from the Michael J. Fox Foundation to accelerate its development for Parkinson's disease and related disorders, with potential for early diagnosis and monitoring [6][7]. - The company is advancing multiple clinical pipelines, including 9MW2821 for bladder cancer and 9MW1911 for COPD, with significant milestones expected in the coming years [8][9].